---
canonical_name: Canagliflozin
alternate_names: Invokana, JNJ-28431754, TA-7284, Canagliflozin Hemihydrate
canonical_topic: Canagliflozin for Health & Longevity
short_topic_lc: canagliflozin
creation_date: 2026-0718-1531
creator_ai_fullname: Opus 4.8
ep_keywords: SGLT2 Inhibitors, Sodium-Glucose Cotransporter-2 Inhibitors, Gliflozins
---

# Canagliflozin for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/18/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Invokana, JNJ-28431754, TA-7284, Canagliflozin Hemihydrate


## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the topic. -->

Canagliflozin (brand name Invokana) is a prescription medication first developed to lower blood sugar in people with type 2 diabetes. It works in an unusual way: instead of acting on insulin, it blocks a protein in the kidneys that normally reclaims sugar from the urine, so the body flushes the excess glucose away. This gentle loss of calories through the urine is what has drawn the attention of people focused on healthy aging.

Interest deepened when a rigorous animal-aging research program found that canagliflozin lengthened the lives of male mice — one of only a small handful of compounds ever to do so under its strict testing. Researchers noticed that the drug's whole-body effects resemble those of eating less, which is the most dependable way known to slow aging in laboratory animals. Its proven ability to protect the heart and kidneys in people has added to the curiosity.

This review examines the evidence for and against using canagliflozin as a longevity intervention. It looks at how the drug works, its established benefits and risks, the strength of the human and animal evidence, and the practical and safety considerations relevant to health-focused adults weighing its use beyond its approved purpose.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section collects high-level expert and academic sources that give a substantive overview of canagliflozin and its emerging role in aging science.

<!-- A real-time web search was performed across general search engines and the platforms of the priority experts (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com) for content discussing canagliflozin or the SGLT2 inhibitor class in a health and longevity context. Only Peter Attia had directly relevant, in-depth material; the remaining slots are filled with qualifying academic sources (a primary lifespan study and narrative/mechanistic reviews). Systematic reviews and meta-analyses were deliberately excluded here. -->

* [#148 – Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program](https://peterattiamd.com/richardmiller/) - Peter Attia

  In this long-form interview, physician Peter Attia and Richard Miller — a lead architect of the animal-aging program that first flagged canagliflozin — walk through why the drug extended male-mouse lifespan and how to read the sex-specific results. It is the most accessible expert discussion of the longevity rationale and its limits.

* [Canagliflozin extends life span in genetically heterogeneous male but not female mice](https://pubmed.ncbi.nlm.nih.gov/32990681/) - Miller et al., 2020

  This is the primary report from the National Institute on Aging's Interventions Testing Program showing a roughly 14% increase in median male-mouse lifespan. It is the single most important source behind canagliflozin's longevity reputation and candidly documents the absence of benefit in females.

* [SGLT inhibitors for improving Healthspan and lifespan](https://pubmed.ncbi.nlm.nih.gov/37852518/) - O'Keefe et al., 2023

  A narrative review linking this drug class's metabolic effects to aging biology, summarizing the cardiovascular, kidney, and longevity data for a clinically literate reader. It usefully frames canagliflozin within the broader idea of mimicking the effects of eating less (a caloric-restriction-mimetic).

* [SGLT2 inhibition eliminates senescent cells and alleviates pathological aging](https://pubmed.ncbi.nlm.nih.gov/38816549/) - Katsuumi et al., 2024

  This laboratory study proposes a specific aging-slowing mechanism — clearance of worn-out "senescent" cells that accumulate with age — offering a biological explanation for effects seen beyond blood-sugar control. It is valuable for understanding why the class attracts longevity interest.

* [Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms](https://pubmed.ncbi.nlm.nih.gov/36293181/) - La Grotta et al., 2022

  A focused review cataloguing the molecular pathways through which these drugs may influence aging, with an even-handed treatment of what remains unproven in humans. It complements the mouse data with a mechanistic roadmap.

Note: No content discussing canagliflozin specifically could be found from Rhonda Patrick (foundmyfitness.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), or Life Extension Magazine (lifeextension.com). Peter Attia was the only priority expert with directly relevant material; the remaining four items are qualifying academic sources.


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "Canagliflozin". A dedicated article page was found at https://grokipedia.com/page/Canagliflozin. -->

* [Canagliflozin](https://grokipedia.com/page/Canagliflozin)

  The Grokipedia article gives a broad reference overview of canagliflozin's pharmacology, approved uses, cardiovascular and kidney trial evidence, and safety signals, including its emerging longevity discussion. It is useful as a quickly navigable orientation to the compound.


## Examine

<!-- examine.com was searched directly using the browser tool for "canagliflozin". No dedicated article exists; Examine's database covers dietary supplements and nutrition rather than prescription pharmaceuticals. -->

No Examine article exists for canagliflozin. Canagliflozin is a prescription medication, and Examine.com does not typically cover prescription drugs; its coverage is limited to dietary supplements, foods, and nutrition topics.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "canagliflozin". No dedicated article exists; ConsumerLab tests and reviews dietary supplements and consumer health products, not prescription pharmaceuticals. -->

No ConsumerLab article exists for canagliflozin. Canagliflozin is a prescription medication, and ConsumerLab does not typically cover prescription drugs; its reviews focus on the quality testing of vitamins, supplements, and other consumer health products.


## Systematic Reviews

This section summarizes the highest-quality systematic reviews and meta-analyses on canagliflozin, prioritized by relevance, study size, and recency.

<!-- A real-time PubMed search was performed for "canagliflozin AND (systematic review[Title] OR meta-analysis[Title])", returning over 200 records. The five below were selected for direct relevance to canagliflozin specifically (rather than the whole drug class) and for coverage of efficacy, cardiovascular/renal outcomes, and safety. -->

* [Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/34349651/) - Tian et al., 2021

  Pooling the major cardiovascular and kidney outcome trials, this analysis quantifies canagliflozin's reduction in major cardiovascular events, heart failure hospitalization, and kidney-disease progression. It is the most directly relevant synthesis for the heart- and kidney-protective claims.

* [Effects of canagliflozin on cardiovascular disease risk factors in patients with type 2 diabetes: a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/40604628/) - Aftabi & Aftabi, 2025

  A recent synthesis focused on intermediate risk factors — body weight, blood pressure, and lipid changes — that are especially relevant to a longevity audience interested in metabolic optimization rather than diabetes treatment alone.

* [Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/25124541/) - Yang et al., 2014

  One of the earliest pooled analyses, establishing canagliflozin's blood-sugar-lowering effect and its characteristic side-effect profile of genital infections and osmotic diuresis. It anchors the baseline efficacy and tolerability picture.

* [Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/28411624/) - Bundhun et al., 2017

  This dose-comparison meta-analysis is valuable for anyone considering the lower versus higher dose, showing how the adverse-event burden scales with dose. It informs the risk-benefit balance for off-label longevity use, where the lowest effective dose is often preferred.

* [Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.](https://pubmed.ncbi.nlm.nih.gov/28105986/) - Johnston et al., 2017

  A comprehensive health-technology assessment comparing the three main drugs in the class head-to-head, useful for understanding where canagliflozin sits relative to its alternatives on efficacy and safety.


## Mechanism of Action

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor — a drug class that lowers blood sugar by blocking glucose reabsorption in the kidney). SGLT2 (sodium-glucose cotransporter 2) is a protein in the early part of the kidney's filtering tubule (the proximal tubule) that reclaims most of the glucose the kidney filters out of the blood. By blocking this protein, canagliflozin prevents that reclamation, so a large amount of glucose — on the order of 80–120 grams per day — is lost in the urine. This lowers blood sugar in a way that does not depend on insulin, which is why it works even when the body's insulin response is impaired.

The downstream effects extend well beyond blood sugar, and these are what interest the longevity field:

* **Caloric loss and metabolic shift:** The continuous urinary glucose loss creates a mild, sustained calorie deficit and nudges the body toward burning fat and producing ketones — a metabolic pattern that resembles eating less. Caloric restriction is the most reproducible lifespan-extending intervention in animals, which is the core of the "caloric-restriction-mimetic" hypothesis.

* **Kidney pressure relief:** Delivering more sodium to the far end of the tubule resets a feedback loop (tubuloglomerular feedback) that tightens the vessel feeding each filtering unit, lowering the pressure inside it. This is thought to explain much of the kidney protection.

* **Osmotic diuresis and natriuresis:** The unabsorbed glucose and sodium pull water into the urine, reducing blood volume and blood pressure and easing the workload on the heart.

* **SGLT1 involvement:** At the higher (300 mg) dose, canagliflozin also transiently blocks SGLT1 (sodium-glucose cotransporter 1 — a related transporter in the gut and kidney) in the intestine, blunting the post-meal glucose spike. This dual action distinguishes canagliflozin from more SGLT2-selective drugs in the class.

Where mechanisms are debated: some researchers argue the longevity and cardiovascular benefits flow from the caloric-restriction-like state and ketone production, while others emphasize direct actions such as clearance of senescent ("worn-out") cells, reduced inflammation, and improved heart-muscle energy handling. Both accounts are supported by laboratory data and are not mutually exclusive.

Key pharmacological properties: canagliflozin's half-life is roughly 10.6 hours at 100 mg and 13.1 hours at 300 mg, supporting once-daily dosing. It is highly protein-bound and distributes widely. It is metabolized mainly by attaching sugar groups (glucuronidation) via the enzymes UGT1A9 and UGT2B4 (enzymes in the liver and kidney that tag drugs for elimination), producing inactive metabolites, with only minor involvement of CYP3A4 (a common liver drug-metabolizing enzyme). This means it has relatively few interactions through the usual liver-enzyme pathways.


## Historical Context & Evolution

* **Original intended use:** Canagliflozin was designed as a glucose-lowering drug for type 2 diabetes. It was the first SGLT2 inhibitor approved in the United States (by the U.S. Food and Drug Administration, the FDA, in March 2013), marketed as Invokana and later as a fixed combination with metformin (Invokamet).

* **Why it came to be considered for health optimization:** The drug class was expected only to lower blood sugar modestly, but large outcome trials revealed heart- and kidney-protective effects that appeared too large and too rapid to be explained by glucose control alone. The CANVAS program showed a reduction in major cardiovascular events, and the CREDENCE trial — stopped early for benefit — showed slowed kidney-disease progression. Both pivotal programs were funded by the drug's manufacturer (Janssen), a financial conflict of interest to keep in view when weighing the strength of these benefit claims. These findings redirected attention to the drug's broader physiology.

* **The longevity turn:** In 2020, the National Institute on Aging's Interventions Testing Program reported that canagliflozin extended median lifespan in genetically diverse male mice, placing it among a very short list of compounds (alongside rapamycin, acarbose, and 17α-estradiol) to pass this rigorous multi-site test. The actual finding was a roughly 14% median lifespan increase in males, with no benefit — and a small unfavorable signal — in females. Follow-up work has examined effects on the aged mouse brain and skeleton, and human laboratory studies have proposed clearance of senescent cells as a mechanism.

* **Evolution of scientific opinion:** Early enthusiasm was tempered by the CANVAS finding of increased lower-limb amputations, though this signal was not reproduced in the later CREDENCE and CANVAS-derived analyses, and the labeled amputation warning was subsequently removed by regulators in 2020. Opinion has thus moved from "glucose drug with a worrying safety flag" toward "cardio-renal protective agent with an unresolved longevity signal," but the human lifespan question remains open — no human trial has tested lifespan, and the sex-specific animal results are not fully understood.


## Expected Benefits

Benefits are graded by the strength of the underlying evidence. A critical caveat for this audience: nearly all high-quality human evidence comes from people with type 2 diabetes, established cardiovascular disease, or chronic kidney disease. Whether the same magnitude of benefit applies to metabolically healthy, longevity-oriented adults using the drug off-label is largely unproven, and several benefits may be smaller (or the risk-benefit balance less favorable) in that group.


### High 🟩 🟩 🟩

#### Blood Sugar Control

Canagliflozin reliably lowers blood sugar by causing the kidneys to excrete glucose, an effect independent of insulin. The evidence base is extensive — multiple meta-analyses of dozens of randomized controlled trials (RCTs — studies that randomly assign participants to treatment or placebo to isolate cause and effect). For a longevity audience without diabetes, the practical relevance is a modest lowering of average glucose and post-meal spikes rather than treatment of a disease, and the effect is proportionally smaller in people who start with normal blood sugar.

**Magnitude:** Reduction in hemoglobin A1c (HbA1c — a measure of average blood sugar over roughly three months) of approximately 0.8–1.1 percentage points versus placebo in diabetics; substantially less in non-diabetics.

#### Cardiovascular Event Reduction

In people with type 2 diabetes and high cardiovascular risk, canagliflozin reduces the combined rate of heart attack, stroke, and cardiovascular death. The evidence is from large dedicated outcome trials (the CANVAS program) and their meta-analyses. The benefit appears within months and is thought to stem from lower blood pressure, blood volume, and improved cardiac energy handling rather than glucose lowering alone.

**Magnitude:** Roughly a 14% relative reduction in major adverse cardiovascular events (major adverse cardiovascular events, or MACE — a composite of heart attack, stroke, and cardiovascular death), with a hazard ratio (HR — a measure of how much a treatment changes the rate of an event) near 0.86.

#### Kidney Protection

Canagliflozin slows the progression of kidney disease, reducing the risk of kidney failure, dialysis, and the need for transplant in people with diabetic kidney disease. The pivotal CREDENCE trial was stopped early for clear benefit. The mechanism is a reduction in the pressure inside the kidney's filtering units. This is one of the drug's most robust and clinically important effects.

**Magnitude:** About a 30% relative reduction in the primary kidney composite outcome (hazard ratio near 0.70) in people with diabetic kidney disease.

#### Heart Failure Hospitalization Reduction

Across the outcome trials, canagliflozin consistently lowers hospitalizations for heart failure, a benefit shared across the SGLT2 inhibitor class and now a licensed use for some drugs in it. The effect is early and substantial and is linked to reduced fluid overload and improved cardiac efficiency.

**Magnitude:** Roughly a one-third relative reduction in heart failure hospitalization (hazard ratio near 0.67) in higher-risk diabetic populations.


### Medium 🟩 🟩

#### Weight Reduction

The daily loss of glucose in the urine represents a loss of calories, producing modest, sustained weight loss — mostly fat mass. Unlike many glucose-lowering drugs, canagliflozin does not cause weight gain. For a longevity audience this is often a desirable effect, though the loss plateaus as the body partially compensates by increasing appetite.

**Magnitude:** Approximately 2–3 kg (about 4–7 lb) of weight loss over the first several months, on average.

#### Blood Pressure Reduction

Through mild fluid loss and sodium excretion, canagliflozin lowers blood pressure without raising heart rate. This contributes to its cardiovascular benefit and can be useful for people with high-normal or elevated blood pressure.

**Magnitude:** A fall in systolic (top-number) blood pressure of roughly 4–5 mmHg and diastolic (bottom-number) of roughly 1–2 mmHg.

#### Uric Acid Reduction

Canagliflozin increases urinary excretion of uric acid, modestly lowering blood levels. This may benefit people prone to gout or with elevated uric acid, a marker associated with metabolic and cardiovascular risk.

**Magnitude:** Roughly a 10–15% reduction in serum uric acid.


### Low 🟩

#### Liver Fat Reduction

By reducing overall calorie load and shifting metabolism toward fat burning, canagliflozin appears to reduce fat accumulation in the liver, of interest for metabolic-associated fatty liver disease. Evidence is from smaller studies and imaging substudies rather than large outcome trials.

**Magnitude:** Reductions in liver fat on imaging broadly comparable to those achieved by the drug's modest (2–3 kg) weight loss, alongside small declines in liver enzymes (ALT).

#### Increase in Red Blood Cells

SGLT2 inhibitors raise hemoglobin and hematocrit (the proportion of blood made up of red cells), thought to reflect improved oxygen sensing in the kidney and mild fluid loss. This may modestly improve oxygen delivery, though the longevity relevance is unproven.

**Magnitude:** A rise in hematocrit of roughly 2–3 percentage points.


### Speculative 🟨

#### Lifespan Extension

The headline longevity claim rests on the 2020 Interventions Testing Program result in male mice and on the drug's resemblance to caloric restriction. No human trial has tested lifespan, the female-mouse result was neutral-to-negative, and translation from mice to humans is uncertain. This is the primary reason a longevity audience is interested, but it remains a hypothesis rather than an established benefit.

#### Senescent Cell Clearance

Laboratory studies suggest canagliflozin may help clear senescent ("worn-out") cells and dampen the inflammatory signals they release, a mechanism linked to slower biological aging. Evidence is mechanistic and from animal or cell models only.

#### Cognitive and Brain Protection

Studies in aged mice report improved brain metabolism and reduced neuroinflammation with canagliflozin, and small human trials in diabetes with cognitive impairment are underway. Any benefit to cognition or dementia risk in humans is currently speculative.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** Variation in the UGT1A9 gene (which codes for a key enzyme that clears canagliflozin) can alter drug exposure; reduced-function variants raise blood levels and may increase both effect and side effects. Variation in the SGLT2 gene itself (SLC5A2) can influence baseline glucose handling and, in principle, responsiveness.

* **Baseline biomarker levels:** The glucose-lowering effect is proportional to starting blood sugar — larger in those with high glucose and minimal in those with normal glucose. Baseline kidney function strongly modifies benefit, because the drug's action depends on the amount of glucose the kidney filters; benefit is blunted at low filtration rates.

* **Sex-based differences:** The animal lifespan benefit was seen in males only, with a neutral-to-slightly-negative result in females, possibly reflecting differences in drug metabolism or hormonal environment. Whether a comparable sex difference exists for human longevity effects is unknown, though cardio-renal benefits in humans appear in both sexes.

* **Pre-existing health conditions:** People with established cardiovascular disease, heart failure, or chronic kidney disease derive the largest absolute benefit. Metabolically healthy individuals have less to gain from the disease-outcome endpoints.

* **Age-related considerations:** Older adults may see meaningful cardio-renal benefit but are also more vulnerable to volume depletion and dehydration; the balance shifts with declining kidney function, which is common at the older end of the target range.


## Potential Risks & Side Effects

Risks are graded by evidence strength. As with benefits, most safety data come from diabetic and high-risk populations; some risks (e.g., ketoacidosis, volume depletion) may present differently in metabolically healthy off-label users, and the amputation and fracture signals remain debated.


### High 🟥 🟥 🟥

#### Genital Yeast Infections

The most common side effect: glucose in the urine feeds yeast, causing genital fungal infections (genital mycotic infections). They are usually mild and treatable but can recur, and are far more frequent in women and in uncircumcised men. Good genital hygiene reduces risk. This is a direct and predictable consequence of the drug's mechanism.

**Magnitude:** Roughly a 3–5 fold increased risk; affecting approximately 10–15% of women and 3–5% of men over a year of use.

#### Volume Depletion and Low Blood Pressure on Standing

The mild fluid loss can cause dehydration, dizziness, and a drop in blood pressure on standing (orthostatic hypotension — lightheadedness when rising due to a transient fall in blood pressure), particularly in older adults, those on diuretics ("water pills"), or those with low fluid intake. It is usually manageable with attention to hydration.

**Magnitude:** Occurs in roughly 2–5% of users, higher in the elderly and in those on diuretics.

#### Euglycemic Diabetic Ketoacidosis

Canagliflozin can trigger a dangerous build-up of blood acids (diabetic ketoacidosis, or DKA — a life-threatening rise in ketone acids in the blood) even when blood sugar is only mildly elevated or near-normal, which can delay recognition. Triggers include fasting, very low-carbohydrate diets, illness, surgery, and alcohol. Though uncommon, it is a medical emergency, and the near-normal glucose makes it especially relevant to lean, low-carbohydrate, or fasting-oriented longevity users.

**Magnitude:** Rare (well under 1% per year in diabetics) but serious; risk is elevated by fasting, ketogenic diets, and dehydration.


### Medium 🟥 🟥

#### Lower-Limb Amputation ⚠️ Conflicted

The CANVAS program found an increased rate of amputations, mostly of the toe or foot, prompting an initial regulatory warning. However, the later CREDENCE trial and pooled analyses did not reproduce this signal, and the boxed warning was removed in 2020. The evidence is directly conflicting, and the true risk — if any — is likely small and concentrated in those with pre-existing peripheral artery disease or prior amputation.

**Magnitude:** In CANVAS, roughly 6 versus 3 per 1,000 patient-years (hazard ratio near 1.97); not replicated in later trials.

#### Acute Kidney Injury

Canagliflozin causes an expected, usually harmless initial dip in measured kidney function, but in the setting of dehydration or illness it can occasionally precipitate a more serious acute decline. The long-term effect on the kidney is protective, but the early period and periods of acute illness warrant caution.

**Magnitude:** An initial reversible eGFR (estimated glomerular filtration rate — a measure of kidney filtering capacity) drop of roughly 3–5 mL/min; serious acute kidney injury is uncommon.

#### Bone Fracture ⚠️ Conflicted

The CANVAS program reported an increased fracture rate, but other canagliflozin trials and meta-analyses did not confirm it, making the evidence conflicting. Proposed mechanisms include effects on calcium-phosphate handling and falls from dizziness. Any real effect appears modest and possibly specific to certain higher-risk populations.

**Magnitude:** In CANVAS, roughly 15 versus 12 per 1,000 patient-years; not seen consistently elsewhere.


### Low 🟥

#### Fournier's Gangrene

A rare but severe infection of the tissue around the genitals and perineum (Fournier's gangrene — a rapidly spreading destructive infection of the genital and perineal tissue) has been reported across the SGLT2 inhibitor class in post-marketing surveillance. It is a surgical emergency. While frightening, it is very rare.

**Magnitude:** Not quantified in available studies.

#### Mild Rise in Potassium

Canagliflozin can modestly raise blood potassium, particularly in people with reduced kidney function or those taking other drugs that raise potassium. It is usually mild and monitorable.

**Magnitude:** A small average rise in serum potassium of roughly 0.1 mmol/L; clinically significant hyperkalemia (high blood potassium) occurs in under 5% of users, concentrated in those with reduced kidney function.

#### Small Rise in LDL Cholesterol

A modest increase in low-density lipoprotein (LDL — the "bad" cholesterol that drives artery plaque) has been observed with the class. Its clinical significance is uncertain given the overall cardiovascular benefit, but it is worth monitoring in a longevity context focused on cardiovascular risk.

**Magnitude:** An LDL increase of roughly 3–8%.


### Speculative 🟨

#### Loss of Muscle and Lean Mass

Because the drug induces a calorie deficit, there is a theoretical concern that long-term use in already-lean, non-diabetic individuals could contribute to loss of muscle along with fat, which would be counterproductive for healthy aging. Human data in lean longevity users are lacking.

#### Net Harm in Metabolically Healthy Users

It is possible that the favorable risk-benefit balance seen in diabetic and high-risk populations does not hold in healthy people, where the disease-prevention benefits are smaller but the side effects (infections, volume loss, ketoacidosis risk) persist. This trade-off has not been formally studied.


## Risk-Modifying Factors

* **Genetic polymorphisms:** Reduced-function variants of UGT1A9 (the enzyme clearing the drug) raise drug levels and may increase side effects. There is no established pharmacogenetic test guiding canagliflozin dosing, but people who metabolize the drug slowly may be more prone to volume- and infection-related effects.

* **Baseline biomarker levels:** Low baseline blood pressure or evidence of volume depletion increases the risk of dizziness and dehydration. Low baseline kidney function raises the risk of hyperkalemia and acute kidney injury. Baseline ketone-prone states (low-carbohydrate dieting) raise ketoacidosis risk.

* **Sex-based differences:** Genital yeast infections are substantially more common in women. The unfavorable lifespan signal in female mice raises unresolved questions about whether the benefit-risk balance differs by sex in humans.

* **Pre-existing health conditions:** Peripheral artery disease, prior amputation, or active foot ulcers raise amputation concern; recurrent urinary or genital infections raise infection risk; type 1 diabetes or a ketosis-prone state sharply raises ketoacidosis risk and is a contraindication.

* **Age-related considerations:** Older adults are more susceptible to dehydration, falls from low blood pressure on standing, and acute kidney injury during illness, all of which matter more at the older end of the target range.


## Key Interactions & Contraindications

* **Prescription drug interactions:** Insulin and insulin-secreting drugs (sulfonylureas such as glipizide, glimepiride) raise the risk of low blood sugar when combined — caution, consider lowering their dose. Diuretics ("water pills" such as furosemide, hydrochlorothiazide) add to fluid loss — caution, monitor for dehydration. Canagliflozin can raise blood levels of digoxin (a heart-rhythm and heart-failure drug) — monitor digoxin levels. Enzyme-inducing drugs that speed canagliflozin's breakdown (rifampin, phenytoin, phenobarbital, ritonavir) can reduce its effect — a dose increase may be needed if used together.

* **Over-the-counter medication interactions:** Non-steroidal anti-inflammatory painkillers (NSAIDs such as ibuprofen, naproxen) can add kidney stress and blunt kidney protection, especially during dehydration — caution. Over-the-counter diuretic or laxative products compound fluid loss — caution.

* **Supplement interactions:** Diuretic herbs (dandelion, caffeine in high doses) can add to fluid loss and dehydration — caution. Potassium supplements can compound the mild potassium-raising effect — monitor.

* **Supplements with additive (same-direction) effects:** Supplements that also lower blood sugar — berberine, chromium, alpha-lipoic acid, cinnamon extract — can add to the glucose-lowering effect and raise the chance of low blood sugar, particularly if combined with other glucose-lowering drugs — monitor and consider spacing or dose reduction. Blood-pressure-lowering supplements (magnesium, high-dose fish oil, beetroot/nitrate) may add to canagliflozin's blood-pressure reduction — monitor for dizziness.

* **Other intervention interactions:** Very low-carbohydrate or ketogenic diets, extended fasting, and heavy alcohol use each raise the risk of ketoacidosis when combined with canagliflozin and are a particularly relevant interaction for the longevity audience — separate the practices or avoid the combination, and hold the drug during prolonged fasts or illness.

* **Populations who should avoid it:** People with type 1 diabetes or a ketosis-prone state (high ketoacidosis risk); those with a history of recurrent genital or urinary infections; those with severe kidney impairment where the drug is ineffective and riskier; those with active lower-limb ulcers, critical limb ischemia, or recent amputation; pregnant or breastfeeding individuals; and those with severe liver impairment (Child-Pugh Class C — the most severe category of liver dysfunction), in whom it has not been studied. Use should be paused before major surgery and during acute serious illness (typically held at least 3 days beforehand for the extended-release setting).


## Risk Mitigation Strategies

* **Low starting dose:** Beginning at 100 mg daily rather than 300 mg reduces the burden of genital infections, volume depletion, and other dose-related effects, which meta-analysis shows scale with dose — a sensible default for off-label longevity use where the goal is not maximal glucose lowering.

* **Hydration discipline:** Maintaining adequate fluid intake (guided by thirst and urine color, with extra attention during heat, exercise, or illness) directly counters the volume-depletion, dizziness, and acute-kidney-injury risks driven by the drug's fluid loss.

* **Sick-day and fasting rules:** Temporarily stopping the drug during acute illness, vomiting, dehydration, extended fasting, or before surgery prevents euglycemic ketoacidosis — the single most important precaution for fasting- or ketogenic-diet-oriented users. Resume only once eating and hydration are normal.

* **Genital hygiene and early treatment:** Routine genital hygiene, prompt drying, and early treatment of any yeast infection reduce recurrence of genital mycotic infections; recurrent or severe infection warrants reconsidering the drug.

* **Foot care and vascular screening:** Regular foot inspection and, for anyone with peripheral artery disease or a prior ulcer, a vascular assessment before starting address the (disputed) amputation signal — avoid use with active foot ulcers or critical limb ischemia.

* **Ketone awareness:** Keeping home ketone testing available and knowing the symptoms of ketoacidosis (nausea, vomiting, abdominal pain, deep breathing, confusion) enables early detection despite near-normal blood sugar, mitigating the euglycemic ketoacidosis risk.

* **Avoid stacking glucose-lowering agents:** Not combining canagliflozin with insulin, sulfonylureas, or multiple glucose-lowering supplements without monitoring prevents dangerous low blood sugar.


## Therapeutic Protocol

Note: canagliflozin is not approved for longevity, so no formal longevity protocol exists. The items below describe how the drug is used clinically and how longevity-focused practitioners have adapted it off-label.

* **Standard dosing:** Clinically, canagliflozin is started at 100 mg once daily and increased to 300 mg once daily if additional glucose lowering is needed and kidney function allows. Longevity-oriented practitioners commonly favor the 100 mg dose to capture metabolic effects while minimizing side effects.

* **Competing approaches:** Within the class, more SGLT2-selective agents (dapagliflozin, empagliflozin) are alternatives with more direct cardiovascular-outcome labeling and, some argue, a cleaner safety record; canagliflozin's distinctive intestinal SGLT1 action at 300 mg is seen by some as a metabolic advantage. Neither the conventional (canagliflozin as a diabetes/cardio-renal drug) nor the integrative (canagliflozin as a caloric-restriction mimetic) framing is established as the default for healthy users.

* **Popularizing sources:** The longevity use case was popularized after the National Institute on Aging's Interventions Testing Program result, and clinician-communicators such as Peter Attia have discussed the class as a candidate geroprotective agent; the diabetes protocol derives from the manufacturer (Janssen) and professional guidelines.

* **Best time of day:** It is taken once daily before the first meal, which optimizes the intestinal SGLT1 effect at the higher dose and provides steady all-day glucose excretion.

* **Half-life:** With a half-life of roughly 10.6–13.1 hours, once-daily dosing maintains its effect across the day and clears within a day or two of stopping.

* **Single versus split dosing:** It is taken as a single daily dose; splitting is neither standard nor supported by its once-daily pharmacology.

* **Genetic polymorphisms:** No pharmacogenetic testing (e.g., of UGT1A9, the clearing enzyme) is routinely used to choose the dose, though slow metabolizers may do better on the lower dose. It is unrelated to the APOE4 (a gene influencing fat transport and dementia risk), MTHFR (a gene involved in folate processing), or COMT (a gene affecting the breakdown of certain neurotransmitters) variants relevant to other longevity interventions, so those do not guide its dosing.

* **Sex-based differences:** Women experience more genital infections and may prefer the lower dose; the male-specific animal lifespan finding has no established dosing implication in humans.

* **Age-related considerations:** In older adults, the lower dose and closer attention to hydration and kidney function are prudent, especially at the older end of the target range.

* **Baseline biomarker levels:** Kidney function (measured before starting) determines both eligibility and expected benefit; blood pressure and volume status guide caution about the diuretic effect.

* **Pre-existing health conditions:** The presence of cardiovascular or kidney disease strengthens the rationale; a ketosis-prone state, recurrent infections, or peripheral artery disease argues against use.


## Discontinuation & Cycling

* **Lifelong versus short-term:** In its approved use, canagliflozin is intended as ongoing, long-term therapy; its benefits (glucose, cardio-renal protection) persist only while it is taken. For off-label longevity use, no evidence defines an optimal duration, and use is generally conceived as continuous rather than a short course.

* **Withdrawal effects:** There are no classic withdrawal symptoms. On stopping, blood sugar, blood pressure, and weight drift back toward their prior baseline over days to weeks, and the initial dip in measured kidney function reverses.

* **Tapering:** No taper is required; because of its short half-life the drug can simply be stopped, and indeed should be stopped abruptly during illness, dehydration, prolonged fasting, or before surgery to avoid ketoacidosis.

* **Cycling:** There is no evidence that cycling maintains efficacy or reduces risk; the drug does not lose effect with continuous use. Some longevity users pause it during planned fasts or ketogenic phases for safety rather than for efficacy reasons.

* **Practical framing:** Any decision to start or stop should account for the fact that the protective effects are present only during active use, so intermittent use sacrifices the sustained cardio-renal benefit that is the drug's best-established value.


## Sourcing and Quality

* **Prescription-only status:** Canagliflozin is a prescription pharmaceutical, so quality is governed by regulatory manufacturing standards rather than by the third-party supplement testing relevant to dietary supplements. It should be obtained through a licensed pharmacy with a valid prescription.

* **Formulations:** It is available as branded Invokana (100 mg and 300 mg tablets) and as fixed-dose combinations with metformin (Invokamet, Invokamet XR). Authorized generic canagliflozin has become available in some markets; where dispensed, it must meet the same bioequivalence standards.

* **Avoiding unregulated sources:** Because of longevity interest, the drug is sometimes sought from online or overseas vendors without prescription; such sources carry risks of counterfeit or substandard product and bypass the medical oversight (kidney function, interaction checks) that safe use requires. Reputable telehealth longevity clinics that prescribe and monitor are a safer route than unverified online pharmacies.

* **What to look for:** A legitimate product carries proper pharmaceutical labeling, lot numbers, and pharmacy dispensing information; the absence of these is a warning sign of a counterfeit.


## Practical Considerations

* **Time to effect:** Glucose lowering and increased urination begin within the first day; blood pressure and weight effects develop over weeks; the cardio-renal protective effects accrue over months. Any longevity benefit, if real, would be a long-horizon proposition with no measurable short-term marker.

* **Common pitfalls:** The most consequential mistakes are continuing the drug while fasting, on a strict ketogenic diet, or during acute illness (raising ketoacidosis risk); under-hydrating; and neglecting genital hygiene. Expecting large weight loss or dramatic short-term effects is another common misjudgment.

* **Regulatory status:** Canagliflozin is FDA-approved for type 2 diabetes, to reduce cardiovascular events in diabetics with cardiovascular disease, and to slow diabetic kidney disease. Use for healthy longevity is off-label — legal when prescribed by a clinician, but outside the approved indications and unsupported by outcome data in healthy people.

* **Cost and accessibility:** Branded canagliflozin can be expensive without insurance, and insurance typically covers it only for approved diabetes or kidney indications, so off-label longevity use is often out-of-pocket. Access generally requires a prescribing clinician willing to supervise off-label use.


## Interaction with Foundational Habits

* **Sleep:** The interaction is mostly indirect. The main practical issue is increased urination, which can cause nighttime waking (nocturia) and disrupt sleep, particularly if the dose is taken late; taking it before the first morning meal minimizes this. There is no direct evidence it improves or worsens sleep architecture.

* **Nutrition:** This is the most important interaction, and it is potentiating in a hazardous direction: combining canagliflozin with very low-carbohydrate or ketogenic diets or extended fasting substantially raises the risk of euglycemic ketoacidosis, because both push the body toward ketone production. Adequate carbohydrate intake and hydration are protective. The drug also causes ongoing calorie and glucose loss, so nutritional planning should account for that deficit. Some users increase magnesium- and potassium-rich foods to offset fluid losses.

* **Exercise:** The interaction is indirect and generally compatible. Exercise plus the drug's glucose loss can lower blood sugar further, so those on other glucose-lowering agents should monitor. Because the drug promotes fat oxidation and mild fluid loss, attention to hydration and electrolytes around intense or endurance exercise is prudent, and there is a theoretical concern about supporting muscle mass, arguing for adequate protein and resistance training.

* **Stress management:** The interaction is indirect. Acute physical stress (illness, injury, surgery) is a key trigger for ketoacidosis and a reason to hold the drug; the drug itself has no established direct effect on cortisol or the psychological stress response. Sound stress and sick-day management is therefore a safety pillar rather than an efficacy lever.


## Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes eligibility and a reference point: kidney function, electrolytes, blood sugar, blood pressure and volume status, and a foot/vascular check in those at risk. Ongoing monitoring focuses on kidney function, hydration, and side effects.

Baseline testing (before starting) and a suggested ongoing cadence — at roughly 2–4 weeks after starting (to catch early volume or kidney effects), then every 3–6 months, and during any acute illness — are summarized below.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| eGFR (estimated glomerular filtration rate) | > 90 mL/min/1.73m² (functional optimum) | Tracks kidney function; determines eligibility and safety | Expect a small reversible dip after starting; conventional labs flag < 60 as reduced. Fasting not required |
| Serum creatinine | 0.7–1.0 mg/dL (lower end of lab range) | Underlies the eGFR estimate; flags acute changes | Rises transiently early; recheck if dehydrated or ill |
| Potassium | 4.0–4.5 mmol/L | Detects the drug's mild potassium-raising effect | Conventional range 3.5–5.0; watch if on other potassium-raising drugs |
| Hemoglobin A1c | < 5.4% (non-diabetic optimum) | Gauges average blood sugar and metabolic effect | Conventional "normal" is < 5.7%; reflects ~3-month average. Fasting not required |
| Fasting glucose | 75–90 mg/dL | Immediate blood-sugar effect | Requires an overnight fast; best measured in the morning |
| Blood pressure | ~110–120 / 70–80 mmHg | Captures the blood-pressure-lowering effect and dehydration risk | Check seated and standing to detect drops on standing; best paired with symptom review |
| LDL cholesterol | < 100 mg/dL (lower for high-risk) | Monitors the small LDL rise seen with the class | Fasting preferred; interpret alongside overall cardiovascular risk |
| Uric acid | 3.5–5.5 mg/dL | Tracks the beneficial urate-lowering effect | Relevant for gout-prone individuals |
| Beta-hydroxybutyrate (blood ketones) | < 0.6 mmol/L (fed state) | Screens for ketoacidosis risk, especially if fasting or low-carb | Measure if symptomatic or during fasting/illness; near-normal glucose can mask ketoacidosis |

Qualitative markers to track alongside labs:

* Energy levels and exercise tolerance
* Frequency of urination and any nighttime waking
* Any genital or urinary infection symptoms
* Thirst, lightheadedness, or dizziness on standing (signs of dehydration)
* Foot condition (any sores, ulcers, or slow-healing wounds)
* Appetite and body-composition changes


## Emerging Research

Research is moving in two directions relevant to this audience: extending the proven cardio-renal benefits into new populations, and testing the still-speculative longevity and healthy-aging hypotheses in humans. Both supportive and cautionary lines of inquiry are noted below.

* **Dedicated healthy-aging human trial:** A small completed study, The Efficacy and Tolerability of Canagliflozin in Healthy Individual ([NCT06301529](https://clinicaltrials.gov/study/NCT06301529)), run by the longevity clinic AgelessRx, tested canagliflozin in healthy, non-diabetic adults (Phase 4, ~30 participants) with a primary focus on changes in blood glucose and tolerability — one of the first direct probes of off-label longevity use in people without diabetes.

* **Prevention across the metabolic spectrum:** The large PRECIDENTD trial ([NCT05390892](https://clinicaltrials.gov/study/NCT05390892); Phase 4, ~6,000 participants) is comparing SGLT2-inhibitor and other glucose-lowering strategies for preventing cardiovascular, kidney, and death events in type 2 diabetes, which will refine where canagliflozin's benefit is greatest.

* **Vascular inflammation mechanism:** The Canagliflozin Targeting Vascular Inflammation study ([NCT05427084](https://clinicaltrials.gov/study/NCT05427084); Phase 2/3) uses imaging to test whether the drug reduces inflammation in the aorta, probing a mechanism potentially shared with its longevity effects.

* **Brain and cognition:** A recruiting trial, Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment ([NCT07711171](https://clinicaltrials.gov/study/NCT07711171); Phase 4), uses brain imaging of blood flow to test cognitive effects, complementing the aged-mouse brain findings.

* **Cancer repurposing:** An early-phase study, Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability Colorectal Cancer ([NCT07076823](https://clinicaltrials.gov/study/NCT07076823); Phase 1), reflects interest in the drug's effects on tumor metabolism — a line that could either strengthen (anti-cancer signal) or complicate the longevity picture.

* **Senescence and aging biology (supportive direction):** Laboratory work by [Katsuumi et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38816549/) proposes that SGLT2 inhibition clears senescent cells and eases age-related decline, and mechanistic reviews such as [La Grotta et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36293181/) map the pathways involved; these could strengthen the case if confirmed in humans.

* **Caveats and counter-evidence (cautionary direction):** The foundational lifespan finding of [Miller et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32990681/) applies to male mice only, with a neutral-to-negative female result, and no human study has tested lifespan or healthspan endpoints; future research clarifying the sex difference and the healthy-user risk-benefit balance could weaken the current enthusiasm. A recent synthesis, [Oshima et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40658498/), continues to refine the class's kidney-outcome profile.


## Conclusion

Canagliflozin is a prescription medication that lowers blood sugar by making the kidneys flush excess glucose into the urine, and its effects reach well beyond blood sugar. In people with diabetes, heart disease, or kidney disease, strong evidence shows it protects the heart and kidneys, reduces hospitalizations for heart failure, and produces modest weight and blood-pressure reductions. These heart- and kidney-protective benefits are its most dependable value. The interest from a longevity standpoint rests on a different foundation: a well-run animal study in which the drug lengthened the lives of male mice, and its broad resemblance to the effects of eating less, the most reliable life-extending approach known in animals.

That longevity promise remains unproven in humans. No human study has measured lifespan, the animal benefit did not extend to females, and it is unclear whether healthy people would gain as much as sick ones while still carrying the real side effects — genital infections, dehydration, and a rare but serious build-up of blood acids that is especially relevant to those who fast or eat very low-carbohydrate diets. The evidence base is strong for disease outcomes but thin and uncertain for healthy aging, and much of that pivotal disease-outcome evidence comes from trials funded by the drug's maker. For someone weighing it beyond its approved use, the established protections are real, while the longevity case is still a promising hypothesis rather than a settled conclusion.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**